VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Saturday, January 10, 2026
Stock Comparison
Union Pacific Corporation vs Vertex Pharmaceuticals Incorporated
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Union Pacific Corporation
UNP · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Union Pacific Corporation's moat claims, evidence, and risks.
View UNP analysisVertex Pharmaceuticals Incorporated
VRTX · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Vertex Pharmaceuticals Incorporated's moat claims, evidence, and risks.
View VRTX analysisComparison highlights
- Moat score gap: Vertex Pharmaceuticals Incorporated leads (99 / 100 vs 72 / 100 for Union Pacific Corporation).
- Segment focus: Union Pacific Corporation has 4 segments (34.8% in Industrial); Vertex Pharmaceuticals Incorporated has 3 segments (99.9% in Cystic Fibrosis CFTR Modulators).
- Primary market structure: Oligopoly vs Quasi-Monopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Union Pacific Corporation has 5 moat types across 2 domains; Vertex Pharmaceuticals Incorporated has 7 across 4.
Primary market context
Union Pacific Corporation
Industrial
Rail freight transportation for industrial commodities (chemicals and plastics, metals and minerals, forest products, energy and specialized markets)
U.S. western two-thirds with interchange to other railroads; cross-border corridors to Mexico and Canada
Chemical producers, refiners, plastics manufacturers, construction and material suppliers, metals and mining, industrial shippers
Class I rail carrier / linehaul freight transport
34.8%
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis CFTR Modulators
CFTR modulator therapies for cystic fibrosis
U.S., Europe, Australia, Canada
Patients (via specialty pharmacies/payers); CF care centers
Drug developer/manufacturer
99.9%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Union Pacific Corporation strengths
Vertex Pharmaceuticals Incorporated strengths
Segment mix
Union Pacific Corporation segments
Full profile >Bulk
Oligopoly
Industrial
Oligopoly
Premium
Oligopoly
Other subsidiary, accessorial and other revenues
Competitive
Vertex Pharmaceuticals Incorporated segments
Full profile >Cystic Fibrosis CFTR Modulators
Quasi-Monopoly
Hemoglobinopathies Gene Therapy (CASGEVY)
Oligopoly
Acute Pain (JOURNAVX)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.